United States CRDMO Market, By Service; By Product; By Application; By End User, Trend Analysis, Competitive Landscape & Forecast, 2019-2031

List of Tables

United States CRDMO Market Size Set to Surpass USD 61.3 Billion by 2031

United States CRDMO (Contract Research, Development, and Manufacturing Organization) Market is flourishing, primarily due to a rising demand for impactful biologics to treat various diseases and complex biopharma manufacturing processes.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated United States CRDMO (Contract Research, Development, and Manufacturing Organization) Market size by value at USD 42.72 billion in 2024. During the forecast period between 2025 and 2031, BlueWeave expects United States CRDMO Market size to boom at a significant CAGR of 5.3% reaching a value of USD 61.33 billion by 2031. A prominent driver of United States CRDMO Market is the rising number of chronic diseases due to population growth, Western lifestyle adoption, and economic development. Pharmaceutical companies are increasingly developing effective medical products to speed up treatment due to the increase in chronic diseases among the rapidly aging global population.

Opportunity - Investments in Continuous Manufacturing Technology

Investments in continuous manufacturing technology present a significant growth opportunity for the players in United States CRDMO Market, offering transformative benefits across efficiency, cost, quality, and supply chain resilience. Continuous manufacturing (CM) replaces traditional batch processes with an uninterrupted production flow, enabling real-time monitoring, automation, and rapid process adjustments. This approach drastically reduces manufacturing cycle times, minimizes human error, and enhances product consistency and quality-key advantages for pharmaceutical and biopharmaceutical companies seeking to accelerate drug development and commercialization. In December 2024, BioCentriq, a leading cell therapy CDMO, signed a long-term lease agreement with National Business Parks for developing a cutting-edge manufacturing facility in Princeton, New Jersey. The facility will also serve as the company's new headquarters with an immediate USD 12 million investment for upgrading the facility with digital advancements.

API Manufacturing Segment Dominates United States CRDMO Market

The active pharmaceutical ingredient (API) manufacturing segment holds a significant market share in United States CRDMO Market, particularly both small molecule and biologic drug development, as well as the increasing complexity and regulatory requirements associated with their production. Additionally, the commercial manufacturing workflow holds the largest share, reflecting strong demand for large-scale drug production to meet the needs of both domestic and global markets. In terms of therapeutic application, oncology stands out as the leading segment, driven by the high prevalence of cancer and significant investments in new cancer therapies.

Impact of Escalating Geopolitical Tensions on United States CRDMO Market

Intensifying geopolitical tensions among countries across the regions are reshaping United States CRDMO Market through being pushed to reduce their reliance on Chinese CDMOs for critical raw materials and manufacturing services. Legislative actions like the proposed BIOSECURE Act and the threat of higher tariffs on Chinese imports are prompting a strategic shift toward reshoring or diversifying supply chains, often favoring domestic or allied international partners, such as those in South Korea and India. In the short term, these changes may lead to supply disruptions or drug shortages as new suppliers are qualified and integrated.

Competitive Landscape

Major players operating in United States CRDMO Market include Pfizer Centreone, Sai Life Sciences, Icosagen, WuXi Biologics, WuXi AppTec, Esco Aster, Jubilant Biosys, Syngene International, Chemveda, Ardena Holding, BioCentriq, Eurofins, and Jiangsu HUAYI Technology Co., Ltd. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The report's in-depth analysis provides information about growth potential, upcoming trends, and United States CRDMO Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in United States CRDMO Market along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Product Code: BWC25308

1. Research Framework

1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Executive Summary

3. United States CRDMO Market Insights

3.1. Industry Value Chain Analysis
3.2. DROC Analysis
- 3.2.1. Drivers
  - 3.2.1.1. Increasing Demand for Biologics
  - 3.2.1.2. Complex Manufacturing Processes
  - 3.2.1.3. Continuous Advancements in Biotechnology
- 3.2.2. Restraints
  - 3.2.2.1. High Regulatory Hurdles
  - 3.2.2.2. Protecting Intellectual Property Rights
  - 3.2.2.3. Capacity Constraints
- 3.2.3. Opportunities
  - 3.2.3.1. Developing Countries with Growing Healthcare Infrastructure
  - 3.2.3.2. Rise of Personalized Medicine
  - 3.2.3.3. Rapid Development of Cell and Gene Therapies
- 3.2.4. Challenges
  - 3.2.4.1. Ensuring the Quality and Consistency of Biologic Products
  - 3.2.4.2. Increasing Competition and Cost Pressures
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry

4. United States CRDMO Market: Marketing Strategies

5. United States CRDMO Market: Pricing Analysis

6. United States CRDMO Market Overview

6.1. Market Size & Forecast, 2019-2031
- 6.1.1. By Value (USD Billion)
6.2. Market Share & Forecast
- 6.2.1. By Service
  - 6.2.1.1. Early phase development services
  - 6.2.1.2. Clinical research services
  - 6.2.1.3. Laboratory services
  - 6.2.1.4. Post-approval services
- 6.2.2. By Product
  - 6.2.2.1. Small molecules
  - 6.2.2.2. Biologics
  - 6.2.2.3. Cell & Gene Therapy
  - 6.2.2.4. Biosimilars
  - 6.2.2.5. Antibody Drug Conjugates
- 6.2.3. By Application
  - 6.2.3.1. Oncology
  - 6.2.3.2. Infectious Disease
  - 6.2.3.3. Neurology
  - 6.2.3.4. Immunology
  - 6.2.3.5. Hematology
  - 6.2.3.6. Vaccine
  - 6.2.3.7. Others
- 6.2.4. By End User
  - 6.2.4.1. Pharmaceutical & Biotech Companies
  - 6.2.4.2. Medical Device Companies
  - 6.2.4.3. Academic & Research Institutes
  - 6.2.4.4. Others

7. Competitive Landscape

7.1. List of Key Players and Their Offerings
7.2. United States CRDMO Market Share Analysis, 2024
- 7.2.1. Competitive Benchmarking, By Operating Parameters
7.3. Key Strategic Developments (Mergers, Acquisitions, Partnerships)

8. Impact of Escalating Geopolitical Tensions on United States CRDMO Market

9. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

9.1. BioDuro-Sundia
9.2. Pfizer Centreone
9.3. Sai Life Sciences
9.4. Icosagen
9.5. WuXi Biologics
9.6. WuXi AppTec
9.7. Esco Aster
9.8. Jubilant Biosys
9.9. Syngene International
9.10. Chemveda
9.11. Ardena Holding
9.12. Eurofins
9.13. Jiangsu HUAYI Technology Co., Ltd
9.14. Other Prominent Players

10. Key Strategic Recommendations

11. Research Methodology

11.1. Qualitative Research
- 11.1.1. Primary & Secondary Research
11.2. Quantitative Research
11.3. Market Breakdown & Data Triangulation
- 11.3.1. Secondary Research
- 11.3.2. Primary Research
11.4. Breakdown of Primary Research Respondents, By Region
11.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable.

Product Code: BWC25308

List of Figures

Figure 1 United States Retail Pharmacy Segmentation
Figure 2 United States CRDMO Market Value Chain Analysis
Figure 3 Company Market Share Analysis, 2024
Figure 4 United States CRDMO Market Size, By Value (USD Billion), 2019-2031
Figure 5 United States CRDMO Market Share, By Product Type , By Value, 2019-2031
Figure 6 United States CRDMO Market Share, By Form, By Value, 2019-2031
Figure 7 United States CRDMO Market Share, By Distribution Channel, By Value, 2019-2031
Figure 8 United States CRDMO Market Share, By Product Type , By Value, 2019-2031
Figure 9 United States CRDMO Market Share, By Form, By Value, 2019-2031

List of Tables

Table 1 United States CRDMO Market Size, By Value (USD Billion), 2019-2031
Table 2 United States CRDMO Market Share, By Product Type , By Value, 2019-2031
Table 3 United States CRDMO Market Share, By Form, By Value, 2019-2031
Table 4 United States CRDMO Market Share, By Distribution Channel, By Value, 2019-2031
Table 5 United States CRDMO Market Share, By Product Type , By Value, 2019-2031
Table 6 United States CRDMO Market Share, By Distribution Channel, By Value, 2019-2031
Table 7 BioDuro-Sundia Company Overview
Table 6 BioDuro-Sundia Financial Overview
Table 7 Pfizer Centreone Company Overview
Table 8 Pfizer Centreone Financial Overview
Table 9 Sai Life Sciences Company Overview
Table 10 Sai Life Sciences Financial Overview
Table 11 Icosagen Company Overview
Table 12 Icosagen Financial Overview
Table 13 WuXi Biologics Company Overview
Table 14 WuXi Biologics Financial Overview
Table 15 WuXi AppTec Company Overview
Table 16 WuXi AppTec Financial Overview
Table 17 Esco Aster Company Overview
Table 18 Esco Aster Financial Overview
Table 19 Jubilant Biosys Company Overview
Table 20 Jubilant Biosys Financial Overview
Table 21 Syngene International Company Overview
Table 22 Syngene International Financial Overview
Table 23 Chemveda Company Overview
Table 24 Chemveda Financial Overview
Table 25 Ardena Holding Company Overview
Table 26 Ardena Holding Financial Overview
Table 27 Eurofins Company Overview
Table 28 Eurofins Financial Overview
Table 29 Jiangsu HUAYI Technology Co., Ltd Company Overview
Table 30 Jiangsu HUAYI Technology Co., Ltd Financial Overview

United States CRDMO Market, By Service; By Product; By Application; By End User, Trend Analysis, Competitive Landscape & Forecast, 2019-2031

Description

Table of Contents

List of Tables

Table of Contents

1. Research Framework

2. Executive Summary

3. United States CRDMO Market Insights

4. United States CRDMO Market: Marketing Strategies

5. United States CRDMO Market: Pricing Analysis

6. United States CRDMO Market Overview

7. Competitive Landscape

8. Impact of Escalating Geopolitical Tensions on United States CRDMO Market

9. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

10. Key Strategic Recommendations

11. Research Methodology

List of Figures

List of Tables